Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs

Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr

EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase

Sanofi’s GPRC5D monoclonal antibody earns ODD in US for multiple myeloma

Beta-HPV can directly cause skin cancer in immunocompromised people

cSCC is one of the most common cancers in the U.S. and globally

NIH develops AI agent to improve accuracy of gene set analysis

The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter

Agilent and TIFR Hyderabad join hands to boost metabolism and health research

iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025

A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide

Maziar Mike Doustdar appointed President and CEO of Novo Nordisk

Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit